ArticleCureus2026
Impact of Imatinib Intake Timing on Oncological Outcomes in Metastatic Gastrointestinal Stromal Tumors (GISTs): A Retrospective Single-Institute Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe time-of-day administration significantly influences treatment outcomes in various cancer settings, particularly with cytotoxic chemotherapy and immunotherapy. However, data regarding tyrosine kinase inhibitors are scarce. We aimed to investigate whether the circadian timing (morning versus evening) of imatinib administration impacts progression-free survival (PFS) in patients with metastatic gastrointestinal stromal tumors (GISTs). A secondary objective was to evaluate the impact of clinical and pathological factors, such as primary tumor site and metastatic burden, on oncological outcomes.
methodsWe conducted a single-center retrospective study on patients with histologically confirmed metastatic GISTs, treated with first-line imatinib (400 mg/day). Patients were categorized into "Morning" (before 12 PM) or "Evening" (after 12 PM) intake groups. The primary endpoint was PFS. Survival curves were estimated using the Kaplan-Meier method and compared using the log-rank test.
resultsForty-four patients were included (median age 54.5 years). The primary tumor sites were mainly gastric n= 20 (45%) and small intestine n= 16 (36%). Hepatic metastases were present in 82% of cases (n= 36). Imatinib was administered in the morning for 59% of patients (n=26) and in the evening for 41% (n=18). Median PFS was 61.5 months in the Morning group versus 26.2 months in the Evening group. Despite this numerical difference, the analysis revealed no statistically significant difference (p=0.22). Gastric primary site (p=0.017) and low metastatic burden (p<0.01) were confirmed as significant favorable prognostic factors.
conclusionIn this cohort, no statistically significant difference in oncological outcomes was detected based on the circadian timing of Imatinib administration. While this suggests a flexible dosing schedule tailored to patient tolerance is reasonable in routine practice, larger, appropriately powered studies incorporating mutational profiling are required to definitively rule out a time-dependent therapeutic effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.